XenoPort to Present Data for Novel Fumarate Analog XP23829 at the 2014 Joint ACTRIMS-ECTRIMS Meeting in Boston
September 10 2014 - 8:30AM
Business Wire
XenoPort, Inc. (Nasdaq:XNPT) announced today that it will
present data on XP23829, an investigational prodrug of monomethyl
fumarate (MMF), at the 2014 Joint ACTRIMS-ECTRIMS Meeting in
Boston. Data being presented include the results from a clinical
trial evaluating the safety, tolerability and pharmacokinetics of
XP23829.
The title of the poster, presentation time and location are as
follows:
XP23829
• Steady state pharmacokinetics and blood
lymphocyte responses in healthy subjects dosed with XP23829, a
novel fumaric acid ester for multiple sclerosis;
Poster 958; Friday, September 12, 2014; 2:45 p.m. ET Location: Hall
C, Poster Exhibition area, 2nd Floor, Hynes Convention Center
About XP23829
XP23829, an experimental drug discovered and currently under
development by XenoPort, is a fumaric acid ester compound that is a
prodrug of MMF. XenoPort is currently evaluating XP23829 in a Phase
2 clinical trial as a potential treatment for moderate-to-severe
chronic plaque-type psoriasis, and XP23829 may be a potential
treatment for relapsing forms of multiple sclerosis (MS).
XP23829 is protected by a composition-of-matter patent that
currently has an expiration date of 2029.
About XenoPort
XenoPort, Inc. is a biopharmaceutical company focused on
developing and commercializing a portfolio of internally discovered
product candidates for the potential treatment of neurological
disorders. XenoPort is currently commercializing HORIZANT®
(gabapentin enacarbil) Extended-Release Tablets in the United
States and developing its novel fumaric acid ester product
candidate, XP23829, as a potential treatment for patients with
moderate-to-severe chronic plaque-type psoriasis and/or relapsing
forms of MS. REGNITE® (gabapentin enacarbil) Extended-Release
Tablets is being marketed in Japan by Astellas Pharma Inc. XenoPort
recently granted exclusive world-wide rights for the development
and commercialization of its clinical-stage oral product candidate,
arbaclofen placarbil, to Reckitt Benckiser Pharmaceuticals, Inc.
for all indications. XenoPort's pipeline of product candidates also
includes a potential treatment for patients with Parkinson's
disease.
To learn more about XenoPort, please visit the website at
www.XenoPort.com.
Forward-Looking Statements
This press release contains “forward-looking” statements,
including, without limitation, all statements related to advancing
the development of XP23829; the suitability of XP23829 as a
potential treatment for moderate-to-severe chronic plaque-type
psoriasis and/or relapsing forms of MS; and the therapeutic and
commercial potential of XP23829. Any statements contained in this
press release that are not statements of historical fact may be
deemed to be forward-looking statements. Words such as “may,”
“potential,” “will” and similar expressions are intended to
identify forward-looking statements. These forward-looking
statements are based upon XenoPort's current expectations.
Forward-looking statements involve risks and uncertainties.
XenoPort's actual results and the timing of events could differ
materially from those anticipated in such forward-looking
statements as a result of these risks and uncertainties, which
include, without limitation: the difficulty and uncertainty of
pharmaceutical product development and the uncertain results and
timing of clinical trials and other studies; XenoPort’s ability to
successfully conduct clinical trials in the anticipated timeframes,
or at all; the risk that XP23829 will require significant
additional clinical testing prior to any possible regulatory
approvals and failure could occur at any stage of its development;
the uncertainty of the regulatory review process and other
regulatory requirements; the uncertainty of protecting and
expanding XenoPort's intellectual property rights, including the
risk that patent rights may not provide XenoPort with sufficient
protection against competitive products or otherwise cover
commercially valuable products or processes; XenoPort's dependence
on potential future collaborative partners; and the uncertain
therapeutic and commercial value of XenoPort's product candidates.
These and other risk factors are discussed under the heading “Risk
Factors” in XenoPort’s Quarterly Report on Form 10-Q for the
quarter ended June 30, 2014 filed with the Securities and Exchange
Commission on August 7, 2014. XenoPort expressly disclaims any
obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained herein to
reflect any change in the company's expectations with regard
thereto or any change in events, conditions or circumstances on
which any such statements are based.
HORIZANT, REGNITE and XENOPORT are registered trademarks of
XenoPort, Inc.
XNPT2G
XenoPort, Inc.Jackie Cossmon, 408-616-7220ir@XenoPort.com
Xenoport, Inc. (NASDAQ:XNPT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Xenoport, Inc. (NASDAQ:XNPT)
Historical Stock Chart
From Apr 2023 to Apr 2024